In people who took tesamorelin, the more their IGF-I levels went up, the better their muscles recovered after exercise — and this link was even stronger than in the whole group.

Scientific Claim

Among obese adults with reduced GH, the increase in IGF-I levels following tesamorelin treatment showed a stronger correlation with improved phosphocreatine recovery (R=0.71, P=0.03) than in the overall cohort, indicating a dose-response relationship within the active treatment group.

Original Statement

“The association between IGF-I and PCr recovery was even stronger among subjects treated with tesamorelin only (ViPCr: R=0.71; P=.03).”

From study:The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The correlation is reported within a treatment group, not as a between-group causal effect. The language 'stronger association' correctly reflects the statistical relationship without implying causation.

Evidence from Studies

Supporting (1)

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Randomized Controlled Trial

Human

2014 Jan

In obese people with low growth hormone, a drug called tesamorelin raised a helpful protein (IGF-I), and the more it rose, the faster their muscles recovered energy after exercise—especially in those who took the drug, not the placebo.

Contradicting (0)

No contradicting evidence found

Source Study

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.

Score: 61

DOI: 10.1210/jc.2013-3436

Similar Assertions

In people who took the placebo, IGF-I didn’t go up much, and their muscle energy recovery didn’t link to IGF-I — meaning the connection only showed up when the drug raised IGF-I.

94%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

90%

Even when researchers removed blurry or low-quality scans, the link between IGF-I and muscle energy recovery stayed strong — so the finding is reliable.

90%

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.

89%

Even though the drug raised IGF-I levels, it didn’t make the muscle energy recovery noticeably better than the placebo — so the effect might be subtle or only show up in certain people.

89%